LanZhou Foci PharmaceuticalLtd Past Earnings Performance
Past criteria checks 1/6
LanZhou Foci PharmaceuticalLtd has been growing earnings at an average annual rate of 1.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 16.6% per year. LanZhou Foci PharmaceuticalLtd's return on equity is 3.5%, and it has net margins of 5.5%.
Key information
1.4%
Earnings growth rate
1.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 16.6% |
| Return on equity | 3.5% |
| Net Margin | 5.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture
Apr 17
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings
Mar 13LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings
Mar 13Revenue & Expenses BreakdownBeta
How LanZhou Foci PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,119 | 62 | 251 | 32 |
| 31 Dec 23 | 1,163 | 67 | 252 | 31 |
| 30 Sep 23 | 1,216 | 111 | 242 | 30 |
| 30 Jun 23 | 1,201 | 111 | 241 | 30 |
| 31 Mar 23 | 1,124 | 111 | 213 | 26 |
| 01 Jan 23 | 1,042 | 109 | 200 | 24 |
| 30 Sep 22 | 852 | 75 | 142 | 23 |
| 30 Jun 22 | 893 | 97 | 161 | 21 |
| 31 Mar 22 | 877 | 92 | 144 | 20 |
| 01 Jan 22 | 818 | 93 | 141 | 19 |
| 30 Sep 21 | 830 | 71 | 154 | 15 |
| 30 Jun 21 | 726 | 58 | 128 | 15 |
| 31 Mar 21 | 708 | 118 | 140 | 12 |
| 31 Dec 20 | 668 | 108 | 124 | 15 |
| 30 Sep 20 | 664 | 110 | 162 | 19 |
| 30 Jun 20 | 646 | 128 | 159 | 20 |
| 31 Mar 20 | 611 | 75 | 155 | 23 |
| 31 Dec 19 | 629 | 75 | 156 | 21 |
| 30 Sep 19 | 607 | 90 | 124 | 19 |
| 30 Jun 19 | 583 | 76 | 118 | 19 |
| 31 Mar 19 | 558 | 65 | 106 | 19 |
| 31 Dec 18 | 545 | 74 | 101 | 20 |
| 30 Sep 18 | 581 | 79 | 104 | 21 |
| 30 Jun 18 | 552 | 82 | 81 | 26 |
| 31 Mar 18 | 543 | 83 | 80 | 22 |
| 31 Dec 17 | 501 | 74 | 79 | 17 |
| 30 Sep 17 | 420 | 66 | 66 | 10 |
| 30 Jun 17 | 405 | 65 | 76 | 0 |
| 31 Mar 17 | 377 | 65 | 73 | 0 |
| 31 Dec 16 | 363 | 61 | 69 | 0 |
| 30 Sep 16 | 337 | 57 | 61 | 0 |
| 30 Jun 16 | 345 | 54 | 61 | 0 |
| 31 Mar 16 | 339 | 46 | 58 | 0 |
| 31 Dec 15 | 328 | 43 | 57 | 0 |
| 30 Sep 15 | 334 | 40 | 58 | 0 |
| 30 Jun 15 | 346 | 38 | 58 | 0 |
| 31 Mar 15 | 371 | 35 | 57 | 0 |
| 31 Dec 14 | 399 | 35 | 60 | 0 |
| 30 Sep 14 | 384 | 34 | 56 | 0 |
| 30 Jun 14 | 358 | 33 | 60 | 0 |
| 31 Mar 14 | 319 | 31 | 63 | 0 |
| 31 Dec 13 | 292 | 31 | 67 | 0 |
| 30 Sep 13 | 284 | 34 | 65 | 0 |
| 30 Jun 13 | 283 | 31 | 64 | 0 |
Quality Earnings: 002644 has a large one-off gain of CN¥15.6M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 002644's current net profit margins (5.5%) are lower than last year (9.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002644's earnings have grown by 1.4% per year over the past 5 years.
Accelerating Growth: 002644's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002644 had negative earnings growth (-44.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 002644's Return on Equity (3.5%) is considered low.